CANCER GENETICS PROGRAM The Cancer Genetics (CG) Program of the UNC Lineberger Comprehensive Cancer Center (LCCC) was established in 2001 to facilitate an integrated, multi-disciplinary approach to genetics research and its application to clinical care. The program is comprised of laboratory-based investigators, statistical geneticists, researchers and clinicians, all focused on improving our understanding of cancer etiology and the treatment of cancer. By integrating the multiple strengths of UNC, ranging from basic science to clinical genomic analysis, the LCCC Cancer Genetics Program has become a world leader in (i) mechanisms of cancer-associated genes; (ii) precision oncology and bioinformatics; and (iii) epigenetics/epigenomics. Cancer treatments are increasingly tailored to an individual?s genomic constitution and the genomic characteristics of the tumor, mitigating toxicity and enhancing efficacy by precisely targeting mutations that drive tumor propagation. We have developed a comprehensive program that includes: (i) integrating diverse experimental organisms from yeast, fly and mouse, to cell-based systems, and ultimately human populations to identify mechanisms that result in genomic and transcriptomic alterations and the specific lesions responsible for cancer phenotypes; (ii) use of Whole Genome, Whole Exome and Whole Transcriptome Sequencing (WGS/WES/WTS) as effective diagnostic tools; (iii) facilitating the meaningful use of genomic information by patients and providers through structured categorization of genomic variation based on clinical validity and utility; (iv) a state-of-the-art informatics approach that incorporates generation, analysis, and management of genomic data, coupling genomic and clinical information to drive both clinical testing and translational research; (v) development of ethical and practical policies for the use of WGS data by clinicians for patient care; and (vi) exploration of epigenomic mechanisms and strategies for therapeutic intervention. Our vision has been realized through value added LCCC resources for the strategic recruitment of faculty in emerging fields, investment in cutting-edge technology including data handling, enhanced organization for integrative analyses and the securing of significant federal funding to enable the application of genomics to diverse aspects of cancer care and prevention. CG consists of 31 members who are associated with 10 basic science and 3 clinical departments at UNC-Chapel Hill and affiliated institutions. During the last funding period, program members have published 544 cancer-related articles, 39% were inter-programmatic and 16% were intra-programmatic (45% collaborative). In 2019, our program members held grants totaling $15.2M (direct cost) in cancer-relevant extramural funding, including $5.7M (direct costs) from the NCI and $8.6M in other peer-reviewed funding.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of North Carolina Chapel Hill
Chapel Hill
United States
Zip Code
Mayer, Deborah K; Landucci, Gina; Awoyinka, Lola et al. (2018) SurvivorCHESS to increase physical activity in colon cancer survivors: can we get them moving? J Cancer Surviv 12:82-94
Huo, Dezheng; Perou, Charles M; Olopade, Olufunmilayo I (2018) Reported Biologic Differences in Breast Cancer by Race Due to Disparities in Screening-Reply. JAMA Oncol 4:883-884
Howe, Chanelle J; Robinson, Whitney R (2018) Survival-related Selection Bias in Studies of Racial Health Disparities: The Importance of the Target Population and Study Design. Epidemiology 29:521-524
Byrne, James D; Yeh, Jen Jen; DeSimone, Joseph M (2018) Use of iontophoresis for the treatment of cancer. J Control Release 284:144-151
Wilkin, Timothy J; Chen, Huichao; Cespedes, Michelle S et al. (2018) A Randomized, Placebo-Controlled Trial of the Quadrivalent Human Papillomavirus Vaccine in Human Immunodeficiency Virus-Infected Adults Aged 27 Years or Older: AIDS Clinical Trials Group Protocol A5298. Clin Infect Dis 67:1339-1346
Siegel, Marni B; He, Xiaping; Hoadley, Katherine A et al. (2018) Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer. J Clin Invest 128:1371-1383
Ubil, Eric; Caskey, Laura; Holtzhausen, Alisha et al. (2018) Tumor-secreted Pros1 inhibits macrophage M1 polarization to reduce antitumor immune response. J Clin Invest 128:2356-2369
Hamad, Ahmad; Iweala, Onyinye I; Henderson, Cory et al. (2018) Recurrent anaphylaxis during cardiac catheterization due to ethylene oxide. J Allergy Clin Immunol Pract 6:2148-2150
Ho, G-T; Aird, R E; Liu, B et al. (2018) MDR1 deficiency impairs mitochondrial homeostasis and promotes intestinal inflammation. Mucosal Immunol 11:120-130
Pearce, Oliver M T; Delaine-Smith, Robin M; Maniati, Eleni et al. (2018) Deconstruction of a Metastatic Tumor Microenvironment Reveals a Common Matrix Response in Human Cancers. Cancer Discov 8:304-319

Showing the most recent 10 out of 1525 publications